Overview Financials News + Filings Key Docs Charts Ownership Insiders |
Stoke Therapeutics, Inc. (STOK)
|
Add to portfolio |
|
|
Price: |
$21.63
| | Metrics |
OS: |
44.3
|
M
| |
-57
|
% ROE
|
Market cap: |
$957
|
M
| |
-225
|
% ROIC
|
Net cash:
|
$231
|
M
| |
$5.23
|
per share
|
EV:
|
$726
|
M
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
|
| |
|
|
EBIT
|
($118)
|
M
| |
|
|
EPS |
($2.57)
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
Revenues | 12.4 | 0.0 | 0.0 | 0.0 | 0.0 | 3.6 |
Revenue growth | | | | | -100.0% | |
Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.6 |
Gross profit | 12.4 | 0.0 | 0.0 | 0.0 | 0.0 | -2.0 |
Gross margin | 100.0% | | | | | -54.4% |
Research and development | 77.8 | 54.2 | 32.2 | 23.8 | 8.4 | |
General and administrative | 38.9 | 31.9 | 20.8 | 11.9 | 4.4 | 2.0 |
EBIT | -104.4 | -86.1 | -53.0 | -35.7 | -12.8 | -5.6 |
EBIT margin | -841.2% | | | | | -154.4% |
Pre-tax income | -101.1 | -85.8 | -52.2 | -32.3 | -12.5 | -5.6 |
Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net income | -101.1 | -85.8 | -52.2 | -32.3 | -12.5 | -5.6 |
Net margin | -814.7% | | | | | -154.5% |
|
Diluted EPS | ($2.60) | ($2.34) | ($1.56) | ($1.80) | ($17.65) | ($8.29) |
Shares outstanding (diluted) | 38.9 | 36.7 | 33.5 | 18.0 | 0.7 | 0.7 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|